Charles River Announces Second-Quarter 2009 Results
Downloadable version.
- Sales Decrease 12.5% to $308 Million
- GAAP Earnings per Share of $0.52 and Non-GAAP Earnings per Share of $0.66
- Updates Sales and EPS Guidance for 2009
- Expands Opportunities Through Strategic Acquisitions and Partnership
WILMINGTON, Mass.--(BUSINESS WIRE)--August 4, 2009--Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2009. For the quarter, net sales decreased 12.5% to $308.2 million from $352.1 million in the second quarter of 2008. Sales declined in both the Research Models and Services (RMS) and Preclinical Services (PCS) segments, reflecting in part the negative impact of foreign exchange, as well as softer market demand for the Company’s broad portfolio of products and services, as pharmaceutical and biotechnology clients reprioritize their drug development pipelines and restructure their operations. Foreign currency translation reduced net sales by 5.1%.
Click here to read the full release.